Zobrazeno 1 - 10 of 608 pro vyhledávání: '"Sootome H"'
1
Akademický článek
[Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi ® Tablets), a covalently-binding, irreversible FGFR1-4 inhibitor].
Autor: Takagaki K; Clinical Development, Medical Affairs Division, Taiho Pharmaceutical Co., Ltd., Okude R; Clinical Development, Medical Affairs Division, Taiho Pharmaceutical Co., Ltd., Hirayama N; Clinical Development, Medical Affairs Division, Taiho Pharmaceutical Co., Ltd., Sootome H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Hirai H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd.
Publikováno v: Nihon yakurigaku zasshi. Folia pharmacologica Japonica [Nihon Yakurigaku Zasshi] 2024 Nov 01; Vol. 159 (6), pp. 423-432. Date of Electronic Publication: 2024 Oct 10.
Zobrazit plný text záznamu
2
Akademický článek
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Autor: Ito S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Otsuki S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Ohsawa H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Hirano A; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Kazuno H; Formulation Research Lab, CMC Division, Taiho Pharmaceutical Co. Ltd., Tokushima, Tokushima 771-0194, Japan., Yamashita S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Egami K; Intellectual Property Department, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan., Shibata Y; MA Project Management Office, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan., Yamamiya I; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Yamashita F; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Kodama Y; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Funabashi K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Kazuno H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Komori T; Regulatory Affairs Department, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan., Suzuki S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Sootome H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Hirai H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan., Sagara T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2023 Mar 10; Vol. 14 (4), pp. 396-404. Date of Electronic Publication: 2023 Mar 10 (Print Publication: 2023).
Zobrazit plný text záznamu
3
Akademický článek
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Autor: Miura A; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.; Graduate School of Technology, Industrial and Social Sciences, Tokushima University, 770-8506, 2-1 Minamijosanjima-cho, Tokushima, Japan., Sootome H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Fujita N; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Suzuki T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Fukushima H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Mizuarai S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Masuko N; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Ito K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Hashimoto A; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Uto Y; Graduate School of Technology, Industrial and Social Sciences, Tokushima University, 770-8506, 2-1 Minamijosanjima-cho, Tokushima, Japan., Sugimoto T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Takahashi H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Mitsuya M; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan., Hirai H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan. Hiroshi-hirai@taiho.co.jp.
Publikováno v: Investigational new drugs [Invest New Drugs] 2021 Jun; Vol. 39 (3), pp. 724-735. Date of Electronic Publication: 2021 Jan 06.
Zobrazit plný text záznamu
5
Akademický článek
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Autor: Sootome H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. h-sohtome@taiho.co.jp., Fujita H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ito K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ochiiwa H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Fujioka Y; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ito K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Miura A; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Sagara T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ito S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Ohsawa H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Otsuki S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Funabashi K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Yashiro M; Department of Surgical Oncology Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan., Matsuo K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan., Yonekura K; Early Development Strategy and Planning, Taiho Pharmaceutical Co., Ltd., Kandanishiki-cho, Tokyo, Japan., Hirai H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Publikováno v: Cancer research [Cancer Res] 2020 Nov 15; Vol. 80 (22), pp. 4986-4997. Date of Electronic Publication: 2020 Sep 24.
Zobrazit plný text záznamu
6
Akademický článek
iPSC-derived megakaryocytes and platelets accelerate wound healing and angiogenesis.
Autor: Kosaka, Kentaro1 (AUTHOR) knt.k-6098@hotmail.co.jp, Takayama, Naoya2 (AUTHOR), Paul, Sudip Kumar2 (AUTHOR), Kanashiro, Maria Alejandra2 (AUTHOR), Oshima, Motohiko3 (AUTHOR), Fukuyo, Masaki4 (AUTHOR), Rahmutulla, Bahityar4 (AUTHOR), Tajiri, Ikuko5 (AUTHOR), Mukai, Michiaki5 (AUTHOR), Kubota, Yoshitaka1 (AUTHOR), Akita, Shinsuke1 (AUTHOR), Furuyama, Nobutaka6 (AUTHOR), Kaneda, Atsushi4,7 (AUTHOR), Iwama, Atsushi3 (AUTHOR), Eto, Koji2,8 (AUTHOR) kojieto@cira.kyoto-u.ac.jp, Mitsukawa, Nobuyuki1 (AUTHOR) nmitsu@faculty.chiba-u.jp
Publikováno v: Stem Cell Research & Therapy. 10/14/2024, Vol. 15 Issue 1, p1-14. 14p.
Zobrazit plný text záznamu
7
Akademický článek
The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.
Autor: Asiri, Abutaleb1,2,3 (AUTHOR) asiriabu@kaimrc.edu.sa, Al Qarni, Ali1,2,3 (AUTHOR) qarniaa@mngha.med.sa, Bakillah, Ahmed1,2,3 (AUTHOR) bakillaha@kaimrc.edu.sa
Publikováno v: Diagnostics (2075-4418). Oct2024, Vol. 14 Issue 19, p2132. 21p.
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo : Preclinical Studies as Guidance for Clinical Development and Trial Design.
Autor: Sootome H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan., Miura A; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan.; Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan., Masuko N; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan., Suzuki T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan., Uto Y; Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan., Hirai H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan. hiroshi-hirai@taiho.co.jp.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Oct; Vol. 19 (10), pp. 1981-1991. Date of Electronic Publication: 2020 Aug 11.
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje